COLON ADENOCARCINOMA
Clinical trials for COLON ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new COLON ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for COLON ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can adding avastin to chemotherapy prevent colon cancer return?
Disease control OngoingThis study tested whether adding the drug bevacizumab (Avastin) to standard chemotherapy helps prevent colon cancer from coming back in patients with stage II colon cancer at high risk for recurrence. Over 2,400 participants who had surgery were randomly assigned to receive eithe…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New combo shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis phase 2 trial is testing a combination of two drugs, cabozantinib and nivolumab, in 48 people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if the combination can shrink or stabilize tumors. All participants have a type of …
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
New vaccine aims to stop colorectal cancer recurrence in High-Risk patients
Disease control OngoingThis study tests an experimental vaccine (RO7198457) in people with stage II or III colorectal cancer who have signs of remaining cancer DNA in their blood after surgery. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiti…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
Immunotherapy combo shows promise in High-Risk colon cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help prevent colon cancer from returning after surgery. It includes 712 people with stage III colon cancer that has a specific DNA repair problem (dMMR). The main goal is to see if th…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New drug cocktail aims to stop BRAF colon cancer in its tracks
Disease control OngoingThis study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…
Matched conditions: COLON ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 12:00 UTC
-
Green tea extract tested to stop colon cancer return
Prevention OngoingThis early-phase study tests whether a green tea extract called EGCG can help prevent colon cancer from returning after surgery. About 51 adults with early-stage colon cancer who have not had other cancer treatments will take EGCG or a placebo before their surgery. Researchers wi…
Matched conditions: COLON ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Prevention
Last updated Jun 18, 2026 11:52 UTC
-
Scientists hunt for genetic clues to rising colorectal cancer in young adults
Knowledge-focused OngoingThis study looks at genetic markers that may increase the risk of developing colorectal cancer at a young age (18-50). Researchers will compare data from 818 patients and their family members to find patterns in genes, treatments, and outcomes. The goal is to better identify who …
Matched conditions: COLON ADENOCARCINOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:48 UTC